Kuber Resources Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Kuber Resources Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.92M | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $2.25M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $1.56M | Apr 16, 2024 |
| FY2011 | Dec 31, 2011 | $15.4K | Mar 29, 2012 |
| FY2011 | Dec 31, 2010 | $18.2K | Mar 29, 2012 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $0 | Apr 30, 2015 |
| FY2014 | Dec 31, 2013 | $0 | Apr 30, 2015 |
| FY2013 | Dec 31, 2012 | $0 | Nov 24, 2014 |
| FY2012 | Dec 31, 2011 | $15.4K | Nov 21, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.49M | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $2.05M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $826.4K | Apr 16, 2024 |
| FY2014 | Dec 31, 2014 | $0 | Apr 30, 2015 |
| FY2014 | Dec 31, 2013 | $0 | Apr 30, 2015 |
| FY2013 | Dec 31, 2012 | $0 | Nov 24, 2014 |
| FY2011 | Dec 31, 2011 | ($26.3K) | Mar 29, 2012 |
| FY2011 | Dec 31, 2010 | ($22.6K) | Mar 29, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.22M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $758.1K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($81.8K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($372.7K) | Apr 14, 2022 |
| FY2014 | Dec 31, 2014 | ($12.3K) | Apr 30, 2015 |
| FY2014 | Dec 31, 2013 | ($11.3K) | Apr 30, 2015 |
| FY2013 | Dec 31, 2012 | ($175.1K) | Nov 24, 2014 |
| FY2011 | Dec 31, 2011 | ($539.1K) | Mar 29, 2012 |
| FY2011 | Dec 31, 2010 | ($824.6K) | Mar 29, 2012 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $971.0K | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $1.69M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $758.1K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($81.8K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($373.7K) | Apr 14, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.60M | Apr 16, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($82.7K) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $201.2K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $12.6K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $50.8K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.8K | Apr 14, 2022 |
| FY2014 | Dec 31, 2014 | ($304) | Apr 30, 2015 |
| FY2013 | Dec 31, 2013 | ($1.3K) | Nov 24, 2014 |
| FY2012 | Dec 31, 2012 | ($108.1K) | Nov 21, 2014 |
| FY2011 | Dec 31, 2011 | ($517.2K) | Mar 29, 2012 |
| FY2011 | Dec 31, 2010 | ($613.2K) | Mar 29, 2012 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $14.4K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $55.2K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.3K | Apr 17, 2023 |
| FY2011 | Dec 31, 2011 | $5.9K | Mar 29, 2012 |
| FY2011 | Dec 31, 2010 | $576 | Mar 29, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.85M | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $5.71M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $1.26M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $57.2K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $5.1K | Apr 14, 2022 |
| FY2014 | Dec 31, 2014 | $236 | Apr 30, 2015 |
| FY2014 | Dec 31, 2013 | $236 | Apr 30, 2015 |
| FY2013 | Dec 31, 2012 | $1.0K | Nov 24, 2014 |
| FY2012 | Dec 31, 2011 | $45.8K | Nov 21, 2014 |
| FY2011 | Dec 31, 2010 | $56.7K | Mar 29, 2012 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.40M | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $1.54M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $484.0K | Apr 16, 2024 |
| FY2011 | Dec 31, 2011 | $3.20M | Mar 29, 2012 |
| FY2011 | Dec 31, 2010 | $2.67M | Mar 29, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.45M | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $4.17M | Apr 16, 2025 |
| FY2024 | Dec 31, 2022 | $772.6K | Apr 16, 2025 |
| FY2023 | Dec 31, 2021 | ($345.5K) | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | ($263.7K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | ($167.6K) | Apr 14, 2022 |
| FY2014 | Dec 31, 2014 | ($3.36M) | Apr 30, 2015 |
| FY2014 | Dec 31, 2013 | ($3.35M) | Apr 30, 2015 |
| FY2014 | Dec 31, 2012 | ($3.34M) | Apr 30, 2015 |
| FY2013 | Dec 31, 2011 | ($3.16M) | Nov 24, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.00M) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($2.07M) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($3.29M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($4.04M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($3.96M) | Apr 14, 2022 |
| FY2014 | Dec 31, 2014 | ($3.56M) | Apr 30, 2015 |
| FY2014 | Dec 31, 2013 | ($3.54M) | Apr 30, 2015 |
| FY2013 | Dec 31, 2012 | ($3.53M) | Nov 24, 2014 |
| FY2012 | Dec 31, 2011 | ($3.36M) | Nov 21, 2014 |
| FY2011 | Dec 31, 2010 | ($2.82M) | Mar 29, 2012 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $104.3K | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $143.9K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $109.2K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $52.3K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.8K | Apr 14, 2022 |
| FY2014 | Dec 31, 2014 | $236 | Apr 30, 2015 |
| FY2014 | Dec 31, 2013 | $236 | Apr 30, 2015 |
| FY2014 | Dec 31, 2012 | $1.0K | Apr 30, 2015 |
| FY2013 | Dec 31, 2011 | $21.4K | Nov 24, 2014 |
| FY2011 | Jan 3, 2011 | $16.4K | Mar 29, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 132.61M | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | 132.61M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | 132.61M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 32.61M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 32.61M | Apr 14, 2022 |
| FY2014 | Dec 31, 2014 | 2.00M | Apr 30, 2015 |
| FY2014 | Dec 31, 2013 | 2.00M | Apr 30, 2015 |
| FY2013 | Dec 31, 2012 | 2.00M | Nov 24, 2014 |
| FY2012 | Dec 31, 2011 | 2.00M | Nov 21, 2014 |
| FY2011 | Dec 31, 2010 | 2.00M | Mar 29, 2012 |